BioLineRx (BLRX) Stock Price, News & Analysis

Company Overview

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Key Stats

• Today's Range: $5.34 to $5.34
• 50-Day Range: $2.43 to $5.44
• 52-Week Range: $2.30 to $35.60
• Volume: 6,952 shs
• Average Volume: 219,581 shs
• Market Capitalization: $17.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Strong Buy

BioLineRx Stock Analysis - MarketRank™

BioLineRx scored higher than 60% of companies evaluated by MarketBeat, and ranked 394th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

BioLineRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioLineRx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLineRx is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLineRx is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLineRx has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.91% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in BioLineRx has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLineRx does not currently pay a dividend.

Dividend Growth

BioLineRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.91% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in BioLineRx has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

BioLineRx has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for BioLineRx this week, compared to 1 article on an average week.

Search Interest

4 people have searched for BLRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLineRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.10% of the stock of BioLineRx is held by insiders.

Percentage Held by Institutions

Only 1.56% of the stock of BioLineRx is held by institutions.

BLRX Stock Analysis - Frequently Asked Questions

How have BLRX shares performed this year?

BioLineRx's stock was trading at $8.56 at the beginning of 2025. Since then, BLRX shares have decreased by 38.4% and is now trading at $5.27.
View the best growth stocks for 2025 here.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Tuesday, May, 27th. The biotechnology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $2.23. The biotechnology company earned $11.75 million during the quarter, compared to analysts' expectations of $7.72 million. BioLineRx had a negative net margin of 90.57% and a negative trailing twelve-month return on equity of 163.37%.
Read the conference call transcript.

When did BioLineRx's stock split?

BioLineRx's stock reverse split before market open on Thursday, January 30th 2025. The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/27/2025
• Today: 6/06/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLRX
• CIK: 1498403
• Web: www.biolinerx.com
• Phone: (728) 642-9100
• Fax: 972-8642-9101
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.00
• High Stock Price Target: $26.00
• Low Stock Price Target: $26.00
• Potential Upside/Downside: +393.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($8.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -90.57%
• Pretax Margin: -90.57%
• Return on Equity: -163.37%
• Return on Assets: -34.21%

Debt

• Debt-to-Equity Ratio: 2.11
• Current Ratio: 1.52
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $22.34 million
• Price / Sales: 0.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.30 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 3,329,000
• Free Float: 3,292,000
• Market Cap: $17.54 million
• Optionable: Optionable
• Beta: 1.29